ReAlta Life Sciences Completes Oversubscribed $40M Financing to Support Pegtarazimod Phase 2 Development in Hypoxic Ischemic Encephalopathy (HIE) ReAlta Life Sciences Inc. (“ReAlta”), a clinical-stage biopharmaceutical company focused on targeting…
United Therapeutics Corporation Receives U.S. Food and Drug Administration Regenerative Medicine Advanced Therapy (RMAT) Designation for miroliverELAP® in the Treatment of Acute Liver Failure United Therapeutics Corporation (Nasdaq: UTHR), a…
Aurion Biotech Initiates Dosing in Phase 3 ASTRA Study Evaluating AURN001 for Corneal Edema Secondary to Corneal Endothelial Dysfunction Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company…
VION Biosciences Completes Acquisition of CTL, Bolstering Its Functional Immune Monitoring Capabilities VION Biosciences (“VION”), a life sciences company focused on building differentiated capabilities across research, diagnostics, and drug development…
Sidewinder Therapeutics Secures $137 Million Series B to Advance Precision Bispecific ADCs into Clinical Development for Cancer Sidewinder Therapeutics, a biopharmaceutical company focused on advancing next-generation antibody-drug conjugates (ADCs) for…
Merck Launches Tender Offer to Acquire Terns Pharmaceuticals, Inc. Merck & Co., Inc., known as MSD outside the United States and Canada, has officially launched a cash tender offer through…
Allergan Aesthetics Launches Its Third Advanced AMI Training Center in Austin Allergan Aesthetics, a leading global provider of aesthetic medicine solutions and part of AbbVie, has announced the opening of…
enGene Confirms Corporate Name Change to enGene Therapeutics Inc enGene Therapeutics Inc., a clinical-stage biotechnology company focused on the development of non-viral genetic medicines, has announced that it will officially…
Biocon Announces U.S. Commercial Debut of Bosaya™ and Aukelso™, Its Denosumab Biosimilars Biocon Limited, a global innovation-driven biopharmaceutical organization, has announced the commercial launch of two denosumab biosimilars—Bosaya™ and Aukelso™—in…
Shionogi Highlights Real-World Effectiveness of Fetroja/Fetcroja Against MBL-Producing Enterobacterales at ESCMID Global 2026 Shionogi & Co., Ltd. has unveiled new real-world and surveillance data highlighting the clinical utility of cefiderocol…
Gilead to Acquire Tubulis to Enhance Oncology Portfolio with Potentially Best-in-Class ADC and Advanced Platform Gilead Sciences has announced that it has entered into a definitive agreement to acquire Tubulis…
B Capital Selected by AMED as Registered VC to Advance Japan’s Drug Development Ecosystem B Capital, a multi-stage investment firm with a strong focus on healthcare innovation, has announced that…